Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1986 1
1989 1
2007 1
2009 1
2010 1
2011 2
2012 3
2014 1
2015 1
2017 2
2018 4
2019 7
2020 11
2021 7
2022 8
2023 5
2024 4

Text availability

Article attribute

Article type

Publication date

Search Results

53 results

Results by year

Filters applied: . Clear all
Page 1
EGFR-Mutated Pulmonary Choriocarcinoma Combined With Adenocarcinoma.
Shigematsu Y, Nakano K, Uchibori K, Inamura K. Shigematsu Y, et al. Among authors: uchibori k. J Thorac Oncol. 2022 Nov;17(11):1318-1322. doi: 10.1016/j.jtho.2022.07.1146. Epub 2022 Aug 10. J Thorac Oncol. 2022. PMID: 35963570 Free article. No abstract available.
Soluble PD-L1 works as a decoy in lung cancer immunotherapy via alternative polyadenylation.
Sagawa R, Sakata S, Gong B, Seto Y, Takemoto A, Takagi S, Ninomiya H, Yanagitani N, Nakao M, Mun M, Uchibori K, Nishio M, Miyazaki Y, Shiraishi Y, Ogawa S, Kataoka K, Fujita N, Takeuchi K, Katayama R. Sagawa R, et al. Among authors: uchibori k. JCI Insight. 2022 Jan 11;7(1):e153323. doi: 10.1172/jci.insight.153323. JCI Insight. 2022. PMID: 34874919 Free PMC article.
Soluble interleukin-2 receptor as a predictive biomarker for poor efficacy of combination treatment with anti-PD-1/PD-L1 antibodies and chemotherapy in non-small cell lung cancer patients.
Tozuka T, Yanagitani N, Yoshida H, Manabe R, Ogusu S, Tsugitomi R, Sakamoto H, Amino Y, Ariyasu R, Uchibori K, Kitazono S, Seike M, Gemma A, Nishio M. Tozuka T, et al. Among authors: uchibori k. Invest New Drugs. 2023 Jun;41(3):411-420. doi: 10.1007/s10637-023-01358-3. Epub 2023 Apr 14. Invest New Drugs. 2023. PMID: 37058183
Clinical characteristics of patients with KRAS mutation detected by liquid biopsy.
Amino Y, Low SK, Ninomiya H, Kiritani A, Miyadera K, Kakuto S, Akita T, Tsugitomi R, Ariyasu R, Uchibori K, Kitazono S, Yanagitani N, Nishio M. Amino Y, et al. Among authors: uchibori k. Thorac Cancer. 2023 Nov;14(33):3317-3322. doi: 10.1111/1759-7714.15123. Epub 2023 Sep 26. Thorac Cancer. 2023. PMID: 37751775 Free PMC article.
53 results